1074 PK/RO modeling of WTX-124, a tumor-activated IL-2 prodrug, highlights the potential for a substantially improved therapeutic index compared to other IL-2 molecules

• Christopher J Nirschl,
• Kyriakos Economides,
• Kristin Morris,
• Andres Salmeron,
• Daniel J Hicklin,
• Cynthia Seidel-Dugan,
• Kulandayan K Subramanian,
• Randi Isaacs,
• Sameer Chopra,
• Celesztina Domonkos

Affiliations

Christopher J Nirschl

Aff2 grid.21107.350000000121719311ImmunologyJohns Hopkins School of Medicine Baltimore MD USA

Kyriakos Economides

Codiak BiSciences, Andover, MA, USA

Kristin Morris

Werewolf Therapeutics, Watertown, MA, USA

Andres Salmeron

1Werewolf Therapeutics, Cambridge, MA, United States

Daniel J Hicklin

Werewolf Therapeutics, Watertown, MA, USA

Cynthia Seidel-Dugan

Werewolf Therapeutics, Watertown, MA, USA

Kulandayan K Subramanian

7Werewolf Therapeutics, Watertown, MA, USA

Randi Isaacs

7Werewolf Therapeutics, Watertown, MA, USA

Sameer Chopra

Werewolf Therapeutics, Watertown, MA, USA

Celesztina Domonkos

Werewolf Therapeutics, Watertown, MA, USA